Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given an experimental combination of mAbs are still alive. But that therapy is only one of several in development, and it is all hands on deck now to push the programs into the clinic.

The ZMapp antibody cocktail from Mapp Biopharmaceutical Inc. is a composite of different mAbs that Mapp, Defyrus Inc., the Public Health Agency of Canada and the University of Manitoba have been working on for at least two years...